![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
The Pharmacokinetic Interactions of HCV Protease Inhibitor TMC435 with Rilpivirine, Tenofovir, Efavirenz or Raltegravir in Healthy Volunteers
|
|
|
Reported by Jules Levin
19th Conference on Retroviruses and
Opportunistic Infections
Seattle, WA March 5 - 8, 2012
S Ouwerkerk-Mahadevan,1 V Sekar,2 M Peeters,1 and M Beumont-Mauviel1
1 Janssen Research and Development, Beerse, Belgium;
2Janssen Research and Development, Titusville, NJ, USA
![CROI1.gif](../images/030712/030712-5/CROI1.gif)
![CROI2.gif](../images/030712/030712-5/CROI2.gif)
![CROI3.gif](../images/030712/030712-5/CROI3.gif)
![CROI4.gif](../images/030712/030712-5/CROI4.gif)
![CROI5.gif](../images/030712/030712-5/CROI5.gif)
![croi1 1.gif](../images/030912/030912-4/croi1%201.gif)
![croi
2.gif](../images/030912/030912-4/croi%0A2.gif)
![CROI7.gif](../images/030712/030712-5/CROI7.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|